Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

1.

Interstitial lung disease in scleroderma.

Schoenfeld SR, Castelino FV.

Rheum Dis Clin North Am. 2015 May;41(2):237-48. doi: 10.1016/j.rdc.2014.12.005. Epub 2015 Feb 26. Review.

PMID:
25836640
2.

Barriers and facilitators of a career as a physician scientist among rheumatologists in the United States.

Ogdie A, Shah AA, Makris UE, Jiang Y, Nelson AE, Kim AH, Angeles-Han ST, Castelino FV, Golding A, Muscal E, Kahlenberg JM, Barg FK; American College of Rheumatology Early Career Investigator Subcommittee of the Committee on Research.

Arthritis Care Res (Hoboken). 2015 Feb 23. doi: 10.1002/acr.22569. [Epub ahead of print]

PMID:
25708626
3.

A 30-year-old woman with chest pain and coronary artery aneurysms.

Honigberg MC, Wallace ZS, Castelino FV.

Arthritis Care Res (Hoboken). 2014 Sep 12. doi: 10.1002/acr.22476. [Epub ahead of print] No abstract available.

PMID:
25220598
4.

Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy.

Castelino FV, Varga J.

Curr Opin Rheumatol. 2014 Nov;26(6):607-14. doi: 10.1097/BOR.0000000000000110. Review.

PMID:
25191991
5.

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials.

Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR; CTD-ILD Special Interest Group.

Thorax. 2014 May;69(5):428-36. doi: 10.1136/thoraxjnl-2013-204202. Epub 2013 Dec 24. Erratum in: Thorax. 2014 Sep;69(9):834. CTD-ILD Special Interest Group [added]; multiple investigator names added.

6.

Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development.

Castelino FV, Varga J.

Expert Rev Clin Immunol. 2013 Nov;9(11):1077-90. doi: 10.1586/1744666X.2013.848792. Review.

PMID:
24168414
7.

Lipids and eicosanoids in fibrosis: emerging targets for therapy.

Castelino FV.

Curr Opin Rheumatol. 2012 Nov;24(6):649-55. Review.

PMID:
22810365
8.

Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma.

Castelino FV, Seiders J, Bain G, Brooks SF, King CD, Swaney JS, Lorrain DS, Chun J, Luster AD, Tager AM.

Arthritis Rheum. 2011 May;63(5):1405-15. doi: 10.1002/art.30262.

9.

Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management.

Castelino FV, Varga J.

Arthritis Res Ther. 2010;12(4):213. doi: 10.1186/ar3097. Epub 2010 Aug 23. Review.

10.

The impact of rheumatological evaluation in the management of patients with interstitial lung disease.

Castelino FV, Goldberg H, Dellaripa PF.

Rheumatology (Oxford). 2011 Mar;50(3):489-93. doi: 10.1093/rheumatology/keq233. Epub 2010 Aug 4.

11.

Tyrosine kinase inhibitors in systemic sclerosis: the case for imatinib.

Castelino FV, Bhattacharyya S, Varga J.

Curr Rheumatol Rep. 2009 Jul;11(3):161-3. No abstract available.

PMID:
19604458
12.

A 36-year-old man with paresthesias and a headache.

Castelino FV, Wasfy JH, Collier D.

Arthritis Rheum. 2008 Sep 15;59(9):1358-65. doi: 10.1002/art.24008. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk